Editorial: Experimental models for the study of drugs used to prevent and treat vascular diseases

Current Pharmaceutical Design

Volumn 14, Issue 4, 2008, Pages 306-308

  Paraskevas, Kosmas I ^a   Mikhailidis, Dimitri P ^a   Thompson, Cecil S ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN E; HOMOCYSTEINE; METHIONINE; NITRIC OXIDE; PLATELET DERIVED GROWTH FACTOR AB; VASCULOTROPIN; VITAMIN B GROUP; ANGIOGENIC FACTOR; ANTIHYPERTENSIVE AGENT; HYPOCHOLESTEROLEMIC AGENT;

ABDOMINAL AORTA ANEURYSM; ANGIOGENESIS; ANIMAL MODEL; ANTIHYPERTENSIVE THERAPY; ARTERY DISEASE; ATHEROSCLEROSIS; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BRAIN DAMAGE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY FAILURE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE MODEL; EDITORIAL; EXPERIMENTAL MODEL; FATTY LIVER; GENETIC MODEL; GENOTYPE; GLUCOSE TOLERANCE; HYPERGLYCEMIA; HYPERHOMOCYSTEINEMIA; HYPERTRIGLYCERIDEMIA; KIDNEY ARTERY STENOSIS; KIDNEY FUNCTION; KNOCKOUT MOUSE; LEG ISCHEMIA; LIPOPROTEIN METABOLISM; METABOLIC SYNDROME X; NEOVASCULARIZATION (PATHOLOGY); NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; RENOVASCULAR HYPERTENSION; RISK FACTOR; STROKE; VASCULAR DISEASE; VASODILATATION; ANIMAL; DRUG DESIGN; HUMAN; KIDNEY FUNCTION TEST; PERIPHERAL VASCULAR DISEASE; SYNTHESIS;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; DISEASE MODELS, ANIMAL; DRUG DESIGN; HUMANS; HYPERHOMOCYSTEINEMIA; HYPOLIPIDEMIC AGENTS; KIDNEY FUNCTION TESTS; PERIPHERAL VASCULAR DISEASES; RENAL ARTERY OBSTRUCTION; VASCULAR DISEASES;

EID: 42049110372     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208783497732     Document Type: Editorial

References (44)

1. Minino AM, Heron MP, Smith BL. Deaths: preliminary data for 2004. Natl Vital Stat Rep 2006; 54: 1-49.
2. Thompson CS. Animal models of diabetes metlitus: relevance to vascular complications. Curr Pharm Des 2008; 14(4): 309-324.
3. Paraskevas KI, Mikhailidis DP, Perrea D. Experimental models of abdominal aortic aneurysms: an overview. Curr Pharm Des 2008; 14(4): 325-337.
4. Kolovou G, Anagnostopoulou K, Mikhailidis DP, Cokkinos DV. Apolipoprotein E knockout models. Curr Pharm Des 2008; 14(4): 338-351.
5. Strbian D, Durukan A, Tatlisumak T. Rodent models of hemorrhagic stroke. Curr Pharm Des 2008; 14(4): 352-358.
6. Durukan A, Strbian D, Tatlisumak T. Rodent models of ischemic stroke: a useful tool for stroke drug development. Curr Pharm Des 2008; 14(4): 359-370.
7. Shiba Y, Takahashi M, Ikeda U. Models for the study of angiogenesis. Curr Pharm Des 2008; 14(4): 371-377.
8. Xirouchakis E, Sigalas A, Manousou P, Calvaruso V, Pleguezuelo M, Corbani A, et al. Models for non-alcoholic fatty liver disease: a link with vascular risk? Curr Pharm Des 2008; 14(4): 378-384.
9. Paraskevas KI, Mikhailidis DP. Angiogenesis: a promising treatment option for peripheral arterial disease. Curr Vasc Pharmacol 2008 (In press).
10. de Nigris F, Williams-Ignarro S, Sica V, D'Armiento FP, Lerman LO, Byrns RE, et al. Therapeutic effects of concurrent autologous bone marrow cell infusion and metabolic intervention in ischemia-induced angiogenesis in the hypercholesterolemic mouse hindlimb. Int J Cardiol 2007; 117: 238-43.
11. He Y, Luo Y, Tang S, Rajantie I, Salven P, Heil M, et al. Critical function of Bmx/Etk in ischemia-mediated arteriogenesis and angiogenesis J Clin Invest 2006; 116: 2344-55.
12. Greve JM, Chico TJ, Goldman H, Bunting S, Peale FV Jr, Daugherty A, et al. Magnetic resonance angiography reveals therapeutic enlargement of collateral vessels induced by VEGF in a murine model of peripheral arterial disease. J Magn Reson Imaging 2006; 24: 1124-32.
13. Yamada N, Li W, Ihaya A, Kimura T, Morioka K, Uesaka T, et al. Platelet-derived endothelial cell growth factor gene therapy for limb ischemia. J Vasc Surg 2006; 44:1322-8.
14. Sampath S, Raval AN, Lederman RJ, McVeigh ER. High-resolution 3D arteriography of chronic total peripheral occlusions using a T1-W turbo spin-echo sequence with inner-volume imaging. Magn Reson Med 2007; 57: 40-9.
15. Dobrucki LW, Sinusas AJ. Imaging angiogenesis. Curr Opin Biotechnol 2007; 18: 90-6.
16. Alnaeb ME, Alobaid N, Seifalian AM, Mikhailidis DP, Hamilton G. Optical techniques in the assessment of peripheral arterial disease. Curr Vasc Pharmacol 2007; 5: 53-9.
17. Penuelas I, Aranguren XL, Abizanda G, Marti-Climent JM, Uriz M. Ecay M, et al. (13)N-ammonia PET as a measurement of hindlimb perfusion in a mouse model of peripheral artery occlusive disease. J Nucl Med 2007; 48: 1216-23.
18. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324: 1149-55.
19. McCully KS. Homocysteine and vascular disease. Nat Med 1996; 2: 386-9.
20. Selhub J, Jacques PF, Bostom AG, D'Agostino RB, Wilson PW, Belanger AJ, et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 1995; 332: 286-91.
21. Zhou J, Moller J, Danielsen CC, Bentzon J, Ravn HB, Austin RC, et al. Hyperhomocysteinemia promotes the development of collagen-rich and stable plaques in apoE-deficient mice. Arterioscler Thromb Vasc Biol 2001; 21: 1470-6.
22. Wang H, Jiang X, Yang F, Gaubatz JW, Ma L, Magera MJ, et al. Hyperhomocysteinemia accelerates atherosclerosis in cystathionine betasynthase and apolipoprotein E double knock-out mice with and without dietary perturbation. Blood 2003; 101: 3901-7.
23. Eberhardt RT, Forgione MA, Cap A, Leopold JA, Rudd MA, Trolliet M, et al. Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia. J Clin Invest 2000; 106: 483-91.
24. Weiss N, Heydrick S, Zhang YY, Bierl C, Cap A, Loscalzo J. Cellular redox state and endothelial dysfunction in mildly hyperhomocysteinemic cystathionine beta-synthase-deficient mice. Arterioscler Thromb Vasc Biol 2002; 22: 34-41.
25. Reddy GS, Wilcken DE. Experimental homocysteinemia in pigs: comparison with studies in sixteen homocystinuric patients. Metabolism 1982; 31: 778-83.
26. Sabbatini M, Tomassoni D, Amenta F. Influence of treatment with Ca(2+) antagonists on cerebral vasculature of spontaneously hypertensive rats. Mech Ageing Dev 2001; 122: 795-809.
27. Sabbatini M, Tomassoni D, Amenta F. Hypertensive brain damage: comparative evaluation of protective effect of treatment with dihydropyridine derivatives in spontaneously hypertensive rats. Mech Ageing Dev 2001; 122: 2085-105.
28. Blezer E, Nicolay K, Goldschmeding R, Koomans H, Joles J. Reduction of cerebral injury in stroke-prone spontaneously hypertensive rats by amlodipine. Eur J Pharmacol 2002; 444: 75-81.
29. Amenta F, Di Tullio MA, Tomassoni D. Arterial hypertension and brain damage - evidence from animal models (review). Clin Exp Hypertens 2003; 25: 359-80.
30. Amenta F, Tomassoni D. Treatment with nicardipine protects brain in an animal model of hypertension-induced damage. Clin Exp Hypertens 2004; 26: 351-61.
31. Dahl LK, Heine M, Tassinari L. Effects of chronic excess salt ingestion. Evidence that genetic factors play an important role in susceptibility to experimental hypertension. J Exp Med 1962; 115: 1173-90.
32. Reaven GM, Twersky J, Chang H. Abnormalities of carbohydrate and lipid metabolism in Dahl rats. Hypertension 1991; 18: 630-5.
33. Klimes I, Vrana A, Kunes J, Sebokova E, Dobesova Z, Stolba P, et al. Hereditary hypertriglyceridemic rat: a new animal model of metabolic alterations in hypertension. Blood Press 1995; 4: 137-42.
34. Chen D, Wang MW. Development and application of rodent models for type 2 diabetes. Diabetes Obesity Metab 2005; 8: 307-17.
35. Aliev G, Burnstock G. Watanabe rabbits with heritable hypercholesterolaemia: a model of atherosclerosis. Histol Histopathol 1998; 13: 797-817.
36. Russell JC, Proctor SD. Small animal models of cardiovascular disease: tools for the study of the roles of metabolic syndrome, dyslipidemia and atherosclerosis. Cardiovasc Pathol 2006; 15: 318-30.
37. Deushi M, Nomura M, Kawakami A, Haraguchi M, Ito M, Okazaki M, et al. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Lett 2007 Nov 15 [Epub ahead of print].
38. Athyros VG, Mikhailidis DP, Didangelos TP, Giouteme OI, Liberopoulos EN, Karagiannis A, et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin 2000; 22: 873-83.
39. Kharin SN, Krandycheva VV. Method of experimental constriction of renal artery for modeling of renovascular hypertension in rats. Bull Exp Biol Med 2004; 138: 103-5.
40. Jackiewicz E, Szczepanska-Sadowska E, Maslinski W. Expression of mineralocorticoid receptors mRNA in the brain, heart and kidney of Sprague Dawley rats with renovascular hypertension. Brain Res Bull 2005; 65: 23-9.
41. Elgort DR, Hillenbrand CM, Zhang S, Wong EY, Rafie S, Lewin JS, et al. Image-guided and -monitored renal artery stenting using only MRI. J Magn Reson Imaging 2006; 23: 619-27.
42. Misra S, Gordon JD, Fu AA, Glockner JF, Chade AR, Mandrekar J, et al. The porcine remnant kidney model of chronic renal insufficiency. J Surg Res 2006; 135: 370-9.
43. Park JK, Rhee T& Cashen TA, Shin W, Schirf BE, Gehl JA, et al. Renal artery stenosis in swine: feasibility of MR assessment of renal function during percutaneous transluminal angioplasty. Radiology 2007; 244: 144-50.
44. Suzuki Y, Ikeno F, Lyons JK, Koizumi T, Yeung AC. Novel stent system for accurate placement in aorto-ostial renal artery disease: preclinical study in porcine renal artery model. Cardiovasc Revasc Med 2007; 8: 99-102.